These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 19638574

  • 1. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Aug 15; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 15; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 7. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH, Shin JY, Kim JO, Oh JE, Yoon SA, Jung CK, Kang JH.
    Cancer Lett; 2012 Sep 28; 322(2):213-22. PubMed ID: 22433711
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.
    Mol Cancer Res; 2007 May 28; 5(5):509-20. PubMed ID: 17510316
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L.
    Clin Lab; 2012 May 28; 58(5-6):551-61. PubMed ID: 22783588
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA, DeNicola GM, Winter SP, Tuveson DA.
    Mol Cell; 2009 Nov 13; 36(3):477-86. PubMed ID: 19917255
    [Abstract] [Full Text] [Related]

  • 15. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 13; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
    Arthan D, Hong SK, Park JI.
    Cancer Lett; 2010 Nov 01; 297(1):31-41. PubMed ID: 20570039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.